Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Upgraded at Zacks Research

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) was upgraded by research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Wednesday,Zacks.com reports.

Other analysts also recently issued reports about the stock. Jefferies Financial Group boosted their target price on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a report on Tuesday, April 28th. Citigroup raised their target price on shares of Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Weiss Ratings upgraded shares of Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, June 8th. Wells Fargo & Company increased their price objective on Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the company an “overweight” rating in a research report on Wednesday, April 29th. Finally, Canaccord Genuity Group raised their price objective on Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. Based on data from MarketBeat.com, Kiniksa Pharmaceuticals International presently has a consensus rating of “Buy” and a consensus target price of $60.86.

Kiniksa Pharmaceuticals International Stock Up 1.7%

NASDAQ:KNSA opened at $55.11 on Wednesday. The business’s 50-day moving average price is $50.86 and its 200 day moving average price is $46.27. The firm has a market cap of $4.24 billion, a P/E ratio of 61.23 and a beta of 0.12. Kiniksa Pharmaceuticals International has a 52-week low of $26.27 and a 52-week high of $59.87.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The firm had revenue of $214.27 million for the quarter, compared to analysts’ expectations of $206.11 million. During the same period in the previous year, the business earned $0.11 earnings per share. Kiniksa Pharmaceuticals International’s revenue for the quarter was up 55.5% compared to the same quarter last year. Sell-side analysts expect that Kiniksa Pharmaceuticals International will post 1.24 EPS for the current year.

Insider Buying and Selling

In related news, Director Barry D. Quart sold 13,099 shares of the company’s stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $50.10, for a total transaction of $656,259.90. Following the transaction, the director directly owned 12,546 shares of the company’s stock, valued at approximately $628,554.60. The trade was a 51.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ross Moat sold 1,703 shares of the stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $46.69, for a total value of $79,513.07. Following the completion of the sale, the chief operating officer directly owned 12,029 shares of the company’s stock, valued at approximately $561,634.01. This represents a 12.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 653,301 shares of company stock valued at $34,046,073. 51.98% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Several institutional investors and hedge funds have recently bought and sold shares of KNSA. EverSource Wealth Advisors LLC lifted its position in shares of Kiniksa Pharmaceuticals International by 140.4% in the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after purchasing an additional 532 shares in the last quarter. Osaic Holdings Inc. purchased a new position in Kiniksa Pharmaceuticals International during the second quarter valued at approximately $31,000. KBC Group NV purchased a new position in Kiniksa Pharmaceuticals International during the first quarter valued at approximately $34,000. Smartleaf Asset Management LLC acquired a new position in Kiniksa Pharmaceuticals International in the 4th quarter valued at approximately $36,000. Finally, Nano Cap New Millennium Growth Fund L P acquired a new position in Kiniksa Pharmaceuticals International in the 4th quarter valued at approximately $41,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.